541/MSS_/Multiple Sclerosis Society/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
1999	1
2000	5
2001	5
2002	5
2003	12
2004	3
2005	8
2006	2
2007	2
2008	1
2012	1
2013	1
2024	0

1

Baker D, Pryce G, Giovannoni G, Thompson AJ. Baker D, et al. Lancet Neurol. 2003 May;2(5):291-8. doi: 10.1016/s1474-4422(03)00381-8. Lancet Neurol. 2003. PMID: 12849183 Review.

2

Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. Baker D, et al. Nature. 2000 Mar 2;404(6773):84-7. doi: 10.1038/35003583. Nature. 2000. PMID: 10716447

3

Gene therapy in autoimmune, demyelinating disease of the central nervous system.

Baker D, Hankey DJ. Baker D, et al. Gene Ther. 2003 May;10(10):844-53. doi: 10.1038/sj.gt.3302025. Gene Ther. 2003. PMID: 12732870 Review.

4

The therapeutic potential of cannabis in multiple sclerosis.

Baker D, Pryce G. Baker D, et al. Expert Opin Investig Drugs. 2003 Apr;12(4):561-7. doi: 10.1517/13543784.12.4.561. Expert Opin Investig Drugs. 2003. PMID: 12665412 Review.

5

Cannabinoids and neuroprotection in CNS inflammatory disease.

Jackson SJ, Diemel LT, Pryce G, Baker D. Jackson SJ, et al. J Neurol Sci. 2005 Jun 15;233(1-2):21-5. doi: 10.1016/j.jns.2005.03.002. J Neurol Sci. 2005. PMID: 15894331 Review.

6

Endocannabinoids control spasticity in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Baker D, et al. FASEB J. 2001 Feb;15(2):300-2. doi: 10.1096/fj.00-0399fje. Epub 2000 Dec 8. FASEB J. 2001. PMID: 11156943

7

New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis.

Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V. Ligresti A, et al. Br J Pharmacol. 2006 Jan;147(1):83-91. doi: 10.1038/sj.bjp.0706418. Br J Pharmacol. 2006. PMID: 16284631 Free PMC article.

8

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Pryce G, et al. Brain. 2003 Oct;126(Pt 10):2191-202. doi: 10.1093/brain/awg224. Epub 2003 Jul 22. Brain. 2003. PMID: 12876144

9

Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) in ABH and SJL mice.

Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S. Morris-Downes MM, et al. J Neuroimmunol. 2002 Jan;122(1-2):20-33. doi: 10.1016/s0165-5728(01)00460-x. J Neuroimmunol. 2002. PMID: 11777540

10

Emerging properties of cannabinoid medicines in management of multiple sclerosis.

Pryce G, Baker D. Pryce G, et al. Trends Neurosci. 2005 May;28(5):272-6. doi: 10.1016/j.tins.2005.03.006. Trends Neurosci. 2005. PMID: 15866202 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

42 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year